Structure-based screen identifies a potent small-molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia

Bypassing tyrosine kinases responsible for Stat5a/b phosphorylation would be advantageous for therapy development for Stat5a/b-regulated cancers. Here, we sought to identify small-molecule inhibitors of Stat5a/b for lead optimization and therapy development for prostate cancer (PC) and Bcr-Abl-drive...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Mol Cancer Ther
المؤلفون الرئيسيون: Liao, Zhiyong, Gu, Lei, Vergalli, Jenny, Mariani, Samanta A., De Dominici, Marco, Lokareddy, Ravi K., Dagvadorj, Ayush, Purushottamachar, Puranik, McCue, Peter A., Trabulsi, Edouard, Lallas, Costas D., Gupta, Shilpa, Ellsworth, Elyse, Blackmon, Shauna, Ertel, Adam, Fortina, Paolo, Leiby, Benjamin, Xia, Guanjun, Rui, Hallgeir, Hoang, David T., Gomella, Leonard G., Cingolani, Gino, Njar, Vincent, Pattabiraman, Nagarajan, Calabretta, Bruno, Nevalainen, Marja T.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2015
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4547362/
https://ncbi.nlm.nih.gov/pubmed/26026053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0883
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة